AbbVie (ABBV) Q1 2026 Earnings
How Did ABBV Stock React to Q1 2026 Earnings?
S&P 500 over the same 30 days: +6.60%.
Did ABBV Beat Earnings? Q1 2026 Results
No. AbbVie reported Q1 2026 earnings of $2.65 a share on Apr 29, 2026, missing the $2.67 consensus estimate by 0.7%. Revenue was $15.0B against a $14.7B estimate.
AbbVie posted a mixed but broadly constructive first quarter for 2026, delivering revenue of $15.00 billion, up 12.4% year over year and ahead of the $14.72 billion consensus, while adjusted diluted EPS of $2.65 came in just shy of the $2.67 analyst estimate, a miss of 0.66%. The earnings shortfall was largely explained by a $744.00 million pre-tax charge tied to acquired in-process research and development and milestones, which shaved $0.41 per share from adjusted results. The immunology franchise carried the quarter, generating $7.29 billion in segment revenue, with Skyrizi climbing 30.9% to $4.48 billion and Rinvoq rising 23.3% to $2.12 billion, more than compensating for Humira's continued erosion to $688.00 million. Neuroscience added further momentum, growing 26.0% to $2.88 billion. Encouraged by the quarter's performance, AbbVie raised its full-year 2026 adjusted EPS guidance to $14.08 to $14.28, from the prior range of $13.96 to $14.16, signaling management's confidence that Skyrizi and Rinvoq can sustain the growth trajectory through the rest of the year.
- Skyrizi net revenues grew 30.9% to $4.483 billion, driven by strong U.S. growth of 29.3% and international growth of 39.8%
- Rinvoq net revenues grew 23.3% to $2.119 billion with broad-based demand
- Neuroscience portfolio up 26.0% with strong contributions from Botox Therapeutic, Vraylar, and the migraine franchise
- Botox Cosmetic grew 20.2%, driving aesthetics portfolio improvement
- Qulipta and Ubrelvy combined grew significantly with 53.6% and 41.4% increases respectively
- Vyalev reached $201 million in quarterly revenue
“We are off to an excellent start in 2026, with first-quarter results exceeding our expectations. AbbVie's key growth drivers continue to deliver strong performance and support our enhanced full-year outlook.”
AbbVie CEO, on the earnings call
What Was AbbVie's Outlook in Q1 2026?
AbbVie raised its full-year 2026 adjusted diluted EPS guidance to $14.08–$14.28, up from the prior range of $13.96–$14.16. This updated guidance includes an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense incurred year-to-date through Q1 2026. The guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond Q1 2026, as both cannot be reliably forecasted.
ABBV YoY Financials
| Metric | Q1 2026 | Q1 2025 | Year over year |
|---|---|---|---|
| Revenue | $15.0B | $13.3B | +12.4% |
| Gross Profit | $10.8B | $9.3B | +15.5% |
| Operating Income | $4.0B | $3.7B | +6.9% |
| Net Income | $695.0M | $1.3B | −46.0% |
ABBV Revenue by Segment
ABBV Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.